Capricor Therapeutics (NASDAQ:CAPR) had its target price boosted by HC Wainwright from $3.50 to $12.40 in a research report released on Monday morning, BenzingaRatingsTable reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.
A number of other analysts have also recently issued reports on the company. ValuEngine cut Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Zacks Investment Research cut Inflarx from a buy rating to a hold rating in a research report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. Capricor Therapeutics has a consensus rating of Hold and a consensus price target of $5.63.
CAPR opened at $5.25 on Monday. Capricor Therapeutics has a 1 year low of $2.53 and a 1 year high of $13.80. The company’s fifty day moving average price is $3.24.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Story: Why is total return important?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.